一类DMOA-Derived Meroterpenoid的全合成研究

DMOA-derived meroterpenoid可根据推测的生物合成途径分为Group I 和Group II。目前的化学合成多是对Group I展开，而对Group II仅有两例核心骨架构建的报道。同属于Group II的emervaridone，emeridone F，emervaridone A，emervaridone B和emervaridone C都具有一个非常独特、复杂的核心桥环骨架，至今没有合成报道。本项目拟以Diels-Alder反应、扩环过程、trans-annular Aldol和Clasen condensation-Aldol condensation为关键转化，为该核心桥环骨架发展有效的构建策略，完成emervaridone，emeridone F，emervaridone A，emervaridone B和emervaridone C的首次不对称全合成。

DMOA-derived meroterpenoid can be divided into Group I and Group II according to proposed biosynthetic pathway. Current chemical synthetic studies are majorly related to Group I. And synthetic studies on Group II are only limited to two reports on construction of the core skeleton. Emervaridone, emeridone F, emervaridone A, emervaridone B and emervaridone C, all belonging to Group II, have a very unique and complex bridged ring skeleton. So far, there is no a synthetic report on them. This project is going to develop an effective construction strategy for the corresponding bridged ring skeleton, with Diels-Alder reaction, ring expansion, trans-annular Aldol and Clasen condensation-Aldol condensation as key transformations. And the asymmetric total synthesis of emervaridone, emeridone F, emervaridone A, emervaridone B and emervaridone C will be achieved for the first time.